Clinical trials: Telangiectasia
Telangiectasia, Hereditary Hemorrhagic
Efficacy of Nintedanib for Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Patients
Patients affected by hereditary hemorrhagic telangiectasia (HHT) very often suffer from recurrent nosebleeds called epistaxis. There is no treatment currently available to reduce the frequency or severity of epistaxis.
- Trial name
- EPISTOP (NCT04976036)
- Testing
- Nintedanib
- Where
- 3 sites in France, Switzerland
- Volunteers
- 48 people
- Sponsor
- Dr. Romain Lazor
Varicose Veins of Lower Limb, Telangiectasia
Efficiency of Determining the Clinical Class of Chronic Venous Disorders by Artificial Intelligence
Purpose: To evaluate the sensitivity and specificity of the method for determining the clinical class of chronic venous diseases using the Ivenus application (within C0-C2 according to CEAP).
- Trial name
- IVENUS (NCT05978986)
- Testing
- Determining of the clinical class of chronic venous disorders by artificial intelligence
- Where
- 3 sites in Russia
- Volunteers
- 1,622 people
- Sponsor
- Clinic of Phlebology and Laser Surgery, Chelyabinsk, Russia
Hereditary Hemorrhagic Telangiectasia (HHT), Pulmonary Hypertension
Efficacy and Tolerance of Treatment With Bevacizumab for Severe Liver Involvement With High Cardiac Output in Hereditary Hemorrhagic Telangiectasia Within the French Hereditary Hemorrhagic Telangiectasia Network
High cardiac output secondary to hepatic arteriovenous malformations may be isolated or associated with left heart failure with post-capillary pulmonary hypertension.
- Conditions
- Hereditary Hemorrhagic Telangiectasia (HHT), Pulmonary Hypertension, Bevacizumab
- Trial name
- BevaHHearT (NCT07445347)
- Testing
- Bevacizumab
- Where
- France
- Volunteers
- 111 people
- Sponsor
- Poitiers University Hospital
Hereditary Haemorrhagic Telangiectasia, PFO - Patent Foramen Ovale
Non-Invasive Detection of Pulmonary Right-to-Left Shunts Using the SONAS Ultrasound Device
The goal of this clinical trial is to learn how well the SONAS ultrasound device can detect right-to-left shunts of adults with hereditary hemorrhagic telangiectasia (HHT) who are already scheduled for a contrast bubble…
- Conditions
- Hereditary Haemorrhagic Telangiectasia, PFO - Patent Foramen Ovale, Pulmonary Arteriovenous Malformation
- Trial name
- SONAS (NCT07414446)
- Testing
- Transcranial Ultrasound Device
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- St. Antonius Hospital
Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer)
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
This is a Phase Ib/II clinical study. The Phase Ib dose-escalation study aims to evaluate and determine the recommended Phase II dose (RP2D) of TCC1727 in combination with benmelstobart /olaparib /topotecanfor patients with…
- Conditions
- Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer), Gastric (Stomach) Cancer, Endometrial Cancer
- Trial name
- NCT07371663
- Testing
- TCC1727 tablet 90mg, TCC1727 tablet 120mg, TCC1727 tablet 160mg
- Where
- 3 sites in China
- Volunteers
- 266 people
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
Macular Telangiectasia
Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1
Idiopathic juxtafoveal telangiectasia type 1 is a rare unilateral disease that mostly affects men before 50 years of age. Mac Tel 1 are characterized by microvascular telangiectasia and increased tortuosity of the macular…
- Trial name
- TELeMAC (NCT03845049)
- Testing
- Inclusion examinations, Aflibercept Injection [Eylea], Examinations during study (every month)
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Macular Telangiectasia Type 2 (MacTel)
Study of Serine Supplementation to Protect Vision in MacTel
The goal of this clinical trial is to look at the efficacy and safety of giving oral serine (an amino acid) on the progression of structural and functional changes of the retina in people with MacTel type 2.
- Trial name
- SEErine (NCT07342439)
- Testing
- L-serine
- Where
- 12 sites in United States, Australia and 3 more
- Volunteers
- 120 people
- Sponsor
- The Lowy Medical Research Institute Limited
Rare Diseases, Amyloidosis
Institutional Registry of Rare Diseases
The goal of this observational study is to create a single macro registry system with data collection on common clinical features, grouping the different rare diseases (RD).
- Conditions
- Rare Diseases, Amyloidosis, Sarcoidosis, Phacomatosis
- Trial name
- NCT06573723
- Where
- Argentina
- Volunteers
- 380 people
- Sponsor
- Hospital Italiano de Buenos Aires
Hemorrhagic Hereditary Telangiectasia
Efficacy and Safety of Bevacizumab for the Treatment Hemorrhagic Hereditary Telangiectasia (HHT) Associated With Severe Hepatic Vascular Malformations. Phase II Study
The efficacy of anti-VEGF treatments such as Bevacizumab in cases of HHT can be considered because of the molecular mechanisms implied in angiogenesis and HHT, as well as the mechanisms of action of this type of treatment.
- Trial name
- METAFORE (NCT00843440)
- Testing
- Bevacizumab
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Hospices Civils de Lyon
Hereditary Hemorrhagic Telangiectasia, Rendu Osler Disease
Stress-Echography in Hereditary Haemorrhagic Telangiectasia Patient With Hepatic Involvement
The hepatic involvement of HHT (Hereditary Haemorrhagic Telangiectasia) disease is characterised by the formation of arterio-sus-hepatic shunts which lead to dilatation of the hepatic artery and may result in high output heart…
- Trial name
- ROSE (NCT05954481)
- Testing
- Stress echocardiography
- Where
- 2 sites in France
- Volunteers
- 47 people
- Sponsor
- Hospices Civils de Lyon
Hereditary Haemorrhagic Telangiectasia
Immunological Effects of Iron Supplementation in HHT Disease
Hereditary haemorrhagic telangiectasia (HHT), is a rare genetic vascular disorder with autosomal dominant inheritance. Its prevalence is estimated at approximately 1 in 6,000 individuals in France.
- Trial name
- Fer&RO (NCT07111598)
- Testing
- Blood test at D0, Blood test at D+3 months
- Where
- France
- Volunteers
- 155 people
- Sponsor
- Hospices Civils de Lyon
Hereditary Hemorrhagic Telangiectasia (HHT)
Description of the Impact of Symptoms on Quality of Life in HHT Disease: DISQUO
In 2017, the ELECT-RO study led, firstly, to the creation of a tool to measure quality of life (QoL) specific to HHT (hereditary haemorrhagic telangiectasia disease), QoL-HHT, based on patients' experiences, their representations…
- Trial name
- DISQUO (NCT07191639)
- Testing
- completion of the QOL-HHT questionnaire
- Where
- France
- Volunteers
- 185 people
- Sponsor
- Hospices Civils de Lyon
Telangiectasia, Hereditary Hemorrhagic, Rendu Osler Disease
Diagnostic Value of Ultra-low Dose Thoracic Scanner for the Pulmonary Arteriovenous Malformation Detection in HHT Patient
Hereditary hemorrhagic telangiectasia (HHT) is linked to a dysregulation of angiogenesis leading to the formation of arteriovenous malformations (AVM): cutaneo-mucous telangiectasia and visceral shunts.
- Trial name
- ULD OSLER (NCT04108052)
- Testing
- Low CT scanner without injection dose, Ultra-low dose CT scanner without injection
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Hospices Civils de Lyon
Hereditary Haemorrhagic Telangiectasia
Genotype Expression and Phenotype of Endothelial Cells, Carrying an ACVRL1, ENG or SMAD4 Mutation, in Response to BMP9 for the Identification of New Therapeutic Targets in Hereditary Haemorrhagic Telangiectasia
Hereditary hemorrhagic telangiectasia (HHT) or Osler-Weber-Rendu syndrome patients are carriers of a heterozygous mutation of the activin receptor-like kinase 1 (ACVRL1), Endoglin (ENG) or Mothers against decapentaplegic homolog…
- Trial name
- CAERO (NCT05632484)
- Testing
- Cord blood sampling, Cord sampling
- Where
- 3 sites in France
- Volunteers
- 16 people
- Sponsor
- Hospices Civils de Lyon
Hereditary Hemorrhagic Telangiectasia
Cardiac Evaluation in Hereditary Hemorrhagic Telangiectasia
Hereditary haemorrhagic telangiectasia (HHT) is a rare autosomal dominant genetic disease associated with mutations in genes encoding proteins of the transforming growth factor β (TGF-β) family, i.e.
- Trial name
- CARDI-HHT (NCT07101575)
- Testing
- Transthoracic echocardiography
- Volunteers
- 380 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Telangiectasia, Hereditary Hemorrhagic, Osler Rendu Disease
Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - (TEMPO)
Timolol is a nonselective β-blocker commonly used in the treatment of glaucoma. Recently it has been used topically for the treatment of superficial hemangiomas.
- Trial name
- TEMPO (NCT02484716)
- Testing
- Timolol nasal spray
- Where
- France
- Volunteers
- 58 people
- Sponsor
- Hospices Civils de Lyon
Rendu Osler Disease, Telangiectasia, Hereditary Hemorrhagic
BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT).
The recognized manifestations of HHT are all due to abnormalities of vascular structure. Epistaxis and digestive arteriovenous malformations may be responsible for severe hemorrhages in 5% of HHT patients, requiring repeated…
- Trial name
- BABH (NCT03227263)
- Testing
- Bevacizumab, sodium chloride 0.9%
- Where
- 4 sites in France
- Volunteers
- 24 people
- Sponsor
- Hospices Civils de Lyon
Telangiectasia, Hereditary Hemorrhagic, Rendu Osler Disease
Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT Disease.
The recognized manifestations of HHT are all due to abnormalities in vascular structure. Epistaxis are spontaneous, very variable, may occur as often as several times every day, and are recurrent in 90% of patients and associated…
- Trial name
- EPICURE (NCT03954782)
- Testing
- Nintedanib 150 mg and 100 mg soft capsules
- Where
- 8 sites in France
- Volunteers
- 61 people
- Sponsor
- Hospices Civils de Lyon
Ataxia-Telangiectasia, Ataxia-Telangiectasia (A-T)
A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T)
A pivotal, randomized, double-blind, placebo-controlled, multi-center therapeutic study for patients age 4 and older with a confirmed diagnosis of Ataxia-Telangiectasia (A-T).
- Trial name
- NCT06673056
- Testing
- N-Acetyl-L-Leucine
- Where
- 11 sites in United States, Germany and 4 more
- Volunteers
- 60 people
- Sponsor
- IntraBio Inc
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- 2 sites in United States, Australia
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health